LOVFF Company Profile and Key Details

The stock is currently within 5% of its 52-week high $1.11 and $1.47. With a market capitalization of about $141.46 million, Cannara Biotech Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.39). Key stats such as the average daily volume over the past year has been around 15.63 thousand shares, volume is running light vs its 52-week average. Headquartered in Saint-Laurent, QC, Cannara Biotech Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Zohar Krivorot, the company employs approximately 452 people and listed since January 18, 2019. Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada.

Average 10-day trading volume of 1.84 thousand shares is below the 3-month average of 19.75 thousand, indicating normal recent market interest.

Cannara Biotech Inc. earnings surprise history is a mixed track record. The quarter that ended July 15, 2026, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -60.01% in April 14, 2026.

Cannara Biotech Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.91. This means the shares are trading below this model’s fair value.

Valuation shows Cannara Biotech Inc. trading at a premium to the broader market with a P/E of 16.88.

Our AI price prediction model suggests that Cannara Biotech Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Cannara Biotech Inc. trades at a P/E ratio of 16.88, slightly below the S&P 500 average, with a price-to-sales ratio of 1.66 and a price-to-book ratio of 2.15 suggesting the stock is closer to book value. The P/FCF stands at 34.35, also above market averages.